BCLI · Brainstorm Cell Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $762.0K | - | $899.0K | $1.12M | $1.30M | - | $1.04M | $922.0K | $961.0K | - |
| SG&A | $1.28M | - | $1.15M | $1.45M | $1.78M | - | $2.00M | $2.06M | $1.51M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $37.0K | - | $48.0K | $51.0K | $52.0K | - | $59.0K | $64.0K | $64.0K | - |
| Operating Income | ($2.05M) | - | ($2.05M) | ($2.57M) | ($3.09M) | - | ($3.05M) | ($2.98M) | ($2.47M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.13M) | - | ($2.11M) | ($2.90M) | ($2.86M) | - | ($2.71M) | ($2.54M) | ($3.40M) | - |
| EPS - Basic | ($0.19) | - | ($0.19) | ($0.34) | ($0.45) | - | ($0.51) | ($0.60) | ($0.75) | - |
| EPS - Diluted | ($0.19) | - | ($0.19) | ($0.34) | ($0.45) | - | ($0.51) | ($0.60) | ($0.75) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.0K | $29.0K | $5.0K | $824.0K | $1.64M | $187.0K | $168.0K | $3.47M | $779.0K | $1.30M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $7.32M | $7.07M | $6.42M | $6.00M | $6.80M | $6.08M | $4.60M | $5.34M | $4.69M | $4.95M |
| Current Assets | $184.0K | $307.0K | $508.0K | $1.51M | $2.33M | $385.0K | $364.0K | $3.82M | $1.26M | $1.90M |
| Total Assets | $755.0K | $1.02M | $1.38M | $2.57M | $3.57M | $1.83M | $2.02M | $5.68M | $3.35M | $4.21M |
| Current Liabilities | $11.76M | $11.01M | $9.02M | $8.53M | $10.90M | $8.98M | $7.08M | $7.69M | $6.83M | $7.80M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $11.76M | $11.01M | $9.07M | $8.62M | $11.03M | $9.60M | $8.08M | $9.21M | $8.90M | $9.07M |
| Stockholders' Equity | ($11.01M) | ($9.98M) | ($7.69M) | ($6.06M) | ($7.46M) | ($7.76M) | ($6.06M) | ($3.53M) | ($5.55M) | ($4.86M) |
| Retained Earnings | ($239.07M) | ($236.94M) | ($234.51M) | - | ($229.50M) | ($226.64M) | ($223.66M) | ($220.96M) | ($218.41M) | ($215.01M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.32M) | - | ($1.10M) | ($3.50M) | ($1.63M) | - | ($3.30M) | ($1.68M) | ($3.06M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $1.25M | - | $313.0K | $2.70M | $3.09M | - | - | $4.37M | $2.54M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -281.7% | - | -152.6% | -113.1% | -80.2% | - | -133.7% | -44.7% | -101.6% | - |
| Return on equity | 19.3% | - | 27.4% | 47.9% | 38.4% | - | 44.7% | 72.0% | 61.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.02 | 0.03 | 0.06 | 0.18 | 0.21 | 0.04 | 0.05 | 0.50 | 0.18 | 0.24 |
| Quick ratio | 0.02 | 0.03 | 0.06 | 0.18 | 0.21 | 0.04 | 0.05 | 0.50 | 0.18 | 0.24 |
| Cash ratio | 0.00 | 0.00 | 0.00 | 0.10 | 0.15 | 0.02 | 0.02 | 0.45 | 0.11 | 0.17 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.07 | -0.10 | -0.18 | -0.42 | -0.48 | -0.24 | -0.33 | -1.61 | -0.60 | -0.87 |
| Liabilities / Assets | 15.58 | 10.77 | 6.57 | 3.36 | 3.09 | 5.24 | 3.99 | 1.62 | 2.66 | 2.15 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 33.8% | - | 32.8% | 13.7% | -24.9% | - | 49.5% | 45.3% | 52.0% | - |
| Net income growth (YoY) | 25.7% | - | 22.2% | -14.2% | 15.8% | - | -120.9% | 52.3% | 32.8% | - |
| EPS growth (YoY) | 57.8% | - | 62.7% | 43.3% | 40.0% | - | -1600.0% | -361.5% | -435.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -47.6% | -28.6% | -27.0% | -71.7% | -34.4% | -59.8% | -134.6% | 9.1% | -14.7% | -61.1% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing BRAINSTORM CELL THERAPEUTICS INC. against the 5 most active filers in the same SIC group.